FX.co ★ GSK Plans To Distribute Over 36 Mln Doses Of Trivalent Influenza Vaccines In The US

GSK (GSK, GSK.L) has commenced the distribution of trivalent influenza vaccines to healthcare providers and pharmacies across the United States, gearing up for the 2024-25 flu season. This follows the recent licensing and lot-release approval from the FDA. GSK plans to distribute over 36 million doses in the U.S.

Both FLULAVAL and FLUARIX vaccines will be available in a 0.5mL, single-dose, pre-filled syringe and are recommended for individuals aged six months and older. These vaccines are designed for active immunization against the influenza A subtype viruses and type B virus included in the formulations.